Koichi Miyake
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Koichi Miyake has a total of 82 co-authors. Here are the top co-authors by number of shared publications:
Takashi Shimada
Department of Biochemistry and Molecular Biology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8602, Japan
12 shared publicationsNoriko Miyake
Department of Biochemistry and Molecular Biology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8602, Japan
10 shared publications- Takashi Shimada
Leading Technology of Bioanalysis and Protein Chemistry, SHIMADZU Corporation, Kyoto, Japan
7 shared publications Osamu Iijima
Department of Biochemistry and Molecular Biology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8602, Japan
5 shared publicationsHideki Hanawa
Department of Biochemistry and Molecular Biology, Division of Gene Therapy Research, Center for Advanced Medical Technology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan
3 shared publicationsTakashi Okada
Department of Biochemistry and Molecular Biology, Nippon Medical School, Tokyo 113-8602 Japan
3 shared publications
Latest Publications
- Open Access
- 9 August 2024
- Published by IntechOpen
Gene Therapy for Hypophosphatasia: Current Management and Future
This review provides a comprehensive overview of hypophosphatasia (HPP), a rare genetic disorder marked by defective bone and teeth mineralization due to mutations in the ALPL gene. It reviews the evolution of HPP treatment, from early symptomatic management methods to the latest therapeutic approaches, emphasizing significant milestones achieved over time. In addition, this review delves into gene therapys historical development, outlining its successes and challenges. Furthermore, it presents a detailed analysis of why this innovative therapy holds promise for HPP, focusing on its efficacy in correcting the underlying biochemical defects and significantly improving patient outcomes. Moreover, the review discusses future research directions, highlighting the critical need for ongoing innovation and rigorous clinical trials to further enhance the efficacy and safety of gene therapy for HPP. Continuous research is essential to developing more effective treatments and ultimately improving the quality of life for patients affected by this debilitating condition.
- 9 August 2024
- Published by IntechOpen
Open AccessGene Therapy for Hypophosphatasia: Current Management and Future
This review provides a comprehensive overview of hypophosphatasia (HPP), a rare genetic disorder marked by defective bone and teeth mineralization due to mutations in the ALPL gene. It reviews the evolution of HPP treatment, from early symptomatic management methods to the latest therapeutic approaches, emphasizing significant milestones achieved over time. In addition, this review delves into gene therapys historical development, outlining its successes and challenges. Furthermore, it presents a detailed analysis of why this innovative therapy holds promise for HPP, focusing on its efficacy in correcting the underlying biochemical defects and significantly improving patient outcomes. Moreover, the review discusses future research directions, highlighting the critical need for ongoing innovation and rigorous clinical trials to further enhance the efficacy and safety of gene therapy for HPP. Continuous research is essential to developing more effective treatments and ultimately improving the quality of life for patients affected by this debilitating condition.
- Open Access
- 7 January 2023
- Published by Adjacent Digital Politics Ltd in Open Access Government
- Vol. 39 (1) , 44-45
Development of a new gene therapy drug as a treatment for hypophosphatasia
Development of a new gene therapy drug as a treatment for hypophosphatasia: The current primary treatment for hypophosphatasia is enzyme replacement therapy however the development of a new gene therapy drug, ARU-2801, may change the landscape forever. Hypophosphatasia (HPP) is a rare bone disease caused by mutations in the ALPL gene, which encodes tissue- nonspecific alkaline phosphatase (TNALP). Symptoms range from mild to severe depending on the patient and are classified into six types according to the age of onset: perinatal lethal form, perinatal benign form, infantile form, childhood form, adult form, and odontohypophosphatasia. If untreated, almost all patients with the perinatal lethal form and about half of those with the infantile form will die.
- 7 January 2023
- Published by Adjacent Digital Politics Ltd in Open Access Government
- Vol. 39 (1) , 44-45
Open AccessDevelopment of a new gene therapy drug as a treatment for hypophosphatasia
Development of a new gene therapy drug as a treatment for hypophosphatasia: The current primary treatment for hypophosphatasia is enzyme replacement therapy however the development of a new gene therapy drug, ARU-2801, may change the landscape forever. Hypophosphatasia (HPP) is a rare bone disease caused by mutations in the ALPL gene, which encodes tissue- nonspecific alkaline phosphatase (TNALP). Symptoms range from mild to severe depending on the patient and are classified into six types according to the age of onset: perinatal lethal form, perinatal benign form, infantile form, childhood form, adult form, and odontohypophosphatasia. If untreated, almost all patients with the perinatal lethal form and about half of those with the infantile form will die.
- Open Access
- 12 June 2021
- Published by Elsevier in Molecular Therapy - Methods & Clinical Development
- Vol. 22, 330-337
Treatment with bone maturation and average lifespan of HPP model mice by AAV8-mediated neonatal gene therapy via single muscle injection
- 12 June 2021
- Published by Elsevier in Molecular Therapy - Methods & Clinical Development
- Vol. 22, 330-337
Open AccessTreatment with bone maturation and average lifespan of HPP model mice by AAV8-mediated neonatal gene therapy via single muscle injection
- Open Access
- 27 June 2018
- Published by IntechOpen
Neonatal Gene Therapy for Inherited Disorders
In spite of developments of neonatal intensive care medicine, it is still difficult or impossible to treat several inherited genetic disorders using conventional pharmacological methods. Gene therapy is a promising alternate approach for treating a variety of genetic disorders. By the time the patient reaches adulthood, however, it is often too late for effective treatment. But in several of these cases, neonatal gene therapy appears potentially useful against inherited disorders that are not obviously treatable through any other methods. This chapter describes the strategy for neonatal gene therapy for inherited disorders and presents preclinical neonatal gene therapy data for two inherited disorders, metachromatic leukodystrophy and hypophosphatasia. We also discuss the utility, advantages, problems and potential of neonatal gene therapy for inherited disorders.
- 27 June 2018
- Published by IntechOpen
Open AccessNeonatal Gene Therapy for Inherited Disorders
In spite of developments of neonatal intensive care medicine, it is still difficult or impossible to treat several inherited genetic disorders using conventional pharmacological methods. Gene therapy is a promising alternate approach for treating a variety of genetic disorders. By the time the patient reaches adulthood, however, it is often too late for effective treatment. But in several of these cases, neonatal gene therapy appears potentially useful against inherited disorders that are not obviously treatable through any other methods. This chapter describes the strategy for neonatal gene therapy for inherited disorders and presents preclinical neonatal gene therapy data for two inherited disorders, metachromatic leukodystrophy and hypophosphatasia. We also discuss the utility, advantages, problems and potential of neonatal gene therapy for inherited disorders.
- Open Access
- 1 January 2017
- Published by Elsevier in Molecular Therapy
- Vol. 25 (1) , 296-302
Improved Intravitreal AAV-Mediated Inner Retinal Gene Transduction after Surgical Internal Limiting Membrane Peeling in Cynomolgus Monkeys
- 1 January 2017
- Published by Elsevier in Molecular Therapy
- Vol. 25 (1) , 296-302
Open AccessImproved Intravitreal AAV-Mediated Inner Retinal Gene Transduction after Surgical Internal Limiting Membrane Peeling in Cynomolgus Monkeys
- Open Access
- 1 May 2016
- Published by Elsevier in Molecular Therapy
- Vol. 24, S63
160. Successful Treatment of Neonatal Metachromatic Leukodystrophy Model Mice by Low Dose of Self-Complementary AAV Type9 Vector Expressing ASA
- 1 May 2016
- Published by Elsevier in Molecular Therapy
- Vol. 24, S63
Open Access160. Successful Treatment of Neonatal Metachromatic Leukodystrophy Model Mice by Low Dose of Self-Complementary AAV Type9 Vector Expressing ASA
- 1 December 2015
- Published by SAGE Publications in Human Gene Therapy
- Vol. 26 (12) , 801-812
Prevention of Lethal Murine Hypophosphatasia by Neonatal Ex Vivo Gene Therapy Using Lentivirally Transduced Bone Marrow Cells
Hypophosphatasia (HPP) is an inherited skeletal and dental disease caused by loss-of-function mutations in the gene that encodes tissue-nonspecific alkaline phosphatase (TNALP). The major symptoms of severe forms of the disease are bone defects, respiratory insufficiency, and epileptic seizures. In 2015, enzyme replacement therapy (ERT) using recombinant bone-targeted TNALP with deca-aspartate (D10) motif was approved to treat pediatric HPP patients in Japan, Canada, and Europe. However, the ERT requires repeated subcutaneous administration of the enzyme because of the short half-life in serum. In the present study, we evaluated the feasibility of neonatal ex vivo gene therapy in TNALP knockout (Akp2−/−) HPP mice using lentivirally transduced bone marrow cells (BMC) expressing bone-targeted TNALP in which a D10 sequence was linked to the C-terminus of soluble TNALP (TNALP-D10). The Akp2−/− mice usually die within 20 days because of growth failure, epileptic seizures, and hypomineralization. However, an intravenous transplantation of BMC expressing TNALP-D10 (ALP-BMC) into neonatal Akp2−/− mice prolonged survival of the mice with improved bone mineralization compared with untransduced BMC-transplanted Akp2−/− mice. The treated Akp2−/− mice were normal in appearance and experienced no seizures during the experimental period. The lentivirally transduced BMC were efficiently engrafted in the recipient mice and supplied TNALP-D10 continuously at a therapeutic level for at least 3 months. Moreover, TNALP-D10 overexpression did not affect multilineage reconstitution in the recipient mice. The plasma ALP activity was sustained at high levels in the treated mice, and tissue ALP activity was selectively detected on bone surfaces, not in the kidneys or other organs. No ectopic calcification was observed in the ALP-BMC-treated mice. These results indicate that lentivirally transduced BMC can serve as a reservoir for stem cell-based ERT to rescue the Akp2−/− phenotype. Neonatal ex vivo gene therapy thus appears to be a possible treatment option for treating severe HPP.
- 1 December 2015
- Published by SAGE Publications in Human Gene Therapy
- Vol. 26 (12) , 801-812
Prevention of Lethal Murine Hypophosphatasia by Neonatal Ex Vivo Gene Therapy Using Lentivirally Transduced Bone Marrow Cells
Hypophosphatasia (HPP) is an inherited skeletal and dental disease caused by loss-of-function mutations in the gene that encodes tissue-nonspecific alkaline phosphatase (TNALP). The major symptoms of severe forms of the disease are bone defects, respiratory insufficiency, and epileptic seizures. In 2015, enzyme replacement therapy (ERT) using recombinant bone-targeted TNALP with deca-aspartate (D10) motif was approved to treat pediatric HPP patients in Japan, Canada, and Europe. However, the ERT requires repeated subcutaneous administration of the enzyme because of the short half-life in serum. In the present study, we evaluated the feasibility of neonatal ex vivo gene therapy in TNALP knockout (Akp2−/−) HPP mice using lentivirally transduced bone marrow cells (BMC) expressing bone-targeted TNALP in which a D10 sequence was linked to the C-terminus of soluble TNALP (TNALP-D10). The Akp2−/− mice usually die within 20 days because of growth failure, epileptic seizures, and hypomineralization. However, an intravenous transplantation of BMC expressing TNALP-D10 (ALP-BMC) into neonatal Akp2−/− mice prolonged survival of the mice with improved bone mineralization compared with untransduced BMC-transplanted Akp2−/− mice. The treated Akp2−/− mice were normal in appearance and experienced no seizures during the experimental period. The lentivirally transduced BMC were efficiently engrafted in the recipient mice and supplied TNALP-D10 continuously at a therapeutic level for at least 3 months. Moreover, TNALP-D10 overexpression did not affect multilineage reconstitution in the recipient mice. The plasma ALP activity was sustained at high levels in the treated mice, and tissue ALP activity was selectively detected on bone surfaces, not in the kidneys or other organs. No ectopic calcification was observed in the ALP-BMC-treated mice. These results indicate that lentivirally transduced BMC can serve as a reservoir for stem cell-based ERT to rescue the Akp2−/− phenotype. Neonatal ex vivo gene therapy thus appears to be a possible treatment option for treating severe HPP.
- Open Access
- 26 November 2015
- Published by IntechOpen
Gene Delivery into the Central Nervous System (CNS) Using AAV Vectors
Application of gene therapies is a promising approach to the treatment of various neurological disorders, including Parkinson's disease, amyotrophic lateral sclerosis (ALS), and lysosomal storage disorders, which are not treatable by any other means. However, the blood-brain barrier (BBB) is a key obstacle to gene delivery to the central nervous system (CNS). Adeno-associated virus (AAV) vectors have emerged as a promising tool for gene delivery to the CNS, thanks to their safety and ability to transduce non-dividing neuronal cells. In this chapter, we discuss strategies for delivering genes across the BBB, focusing especially on potential routes of administration of AAV vectors and promising applications of AAV vectors to the treatment of CNS disorders.
- 26 November 2015
- Published by IntechOpen
Open AccessGene Delivery into the Central Nervous System (CNS) Using AAV Vectors
Application of gene therapies is a promising approach to the treatment of various neurological disorders, including Parkinson's disease, amyotrophic lateral sclerosis (ALS), and lysosomal storage disorders, which are not treatable by any other means. However, the blood-brain barrier (BBB) is a key obstacle to gene delivery to the central nervous system (CNS). Adeno-associated virus (AAV) vectors have emerged as a promising tool for gene delivery to the CNS, thanks to their safety and ability to transduce non-dividing neuronal cells. In this chapter, we discuss strategies for delivering genes across the BBB, focusing especially on potential routes of administration of AAV vectors and promising applications of AAV vectors to the treatment of CNS disorders.
- Open Access
- 1 September 2015
- Published by Wolters Kluwer Health in Plastic and Reconstructive Surgery - Global Open
- Vol. 3 (9) , e520
Tissue Inhibitor of Metalloproteinase-2 Suppresses Collagen Synthesis in Cultured Keloid Fibroblasts
Keloids are defined as a kind of dermal fibroproliferative disorder resulting from the accumulation of collagen. In the remodeling of extracellular matrix, the balance between matrix metalloproteinases (MMPs) and the tissue inhibitors of metalloproteinases (TIMPs) is as critical as the proper production of extracellular matrix. We investigate the role of TIMPs and MMPs in the pathogenesis of keloids and examine the therapeutic potential of TIMP-2. The expression of TIMPs and MMPs in most inflamed parts of cultured keloid fibroblasts (KFs) and peripheral normal skin fibroblasts (PNFs) in the same individuals and the reactivity of KFs to cyclic mechanical stretch were analyzed by quantitative real-time polymerase chain reaction and enzyme-linked immunosorbent assay (n = 7). To evaluate the effect of treating KFs with TIMP-2, collagen synthesis was investigated by quantitative real-time polymerase chain reaction and enzyme-linked immunosorbent assay, and microscopic analysis was used to examine the treatment effects of TIMP-2 on ex vivo cultures of keloid tissue (n = 6). TIMP-2 was downregulated in cultured KFs compared with PNFs in the same individuals, and the reduction in TIMP-2 was exacerbated by cyclic mechanical stretch. Administration of TIMP-2 (200 or 300 ng/mL) significantly suppressed expression of Col1A2 and Col3A1 mRNA and collagen type I protein in KFs. TIMP-2 also significantly reduced the skin dermal and collagen bundle thickness in ex vivo cultures of keloid tissue. These results indicated that downregulation of TIMP-2 in KFs is a crucial event in the pathogenesis of keloids, and the TIMP-2 would be a promising candidate for the treatment of keloids.
- 1 September 2015
- Published by Wolters Kluwer Health in Plastic and Reconstructive Surgery - Global Open
- Vol. 3 (9) , e520
Open AccessTissue Inhibitor of Metalloproteinase-2 Suppresses Collagen Synthesis in Cultured Keloid Fibroblasts
Keloids are defined as a kind of dermal fibroproliferative disorder resulting from the accumulation of collagen. In the remodeling of extracellular matrix, the balance between matrix metalloproteinases (MMPs) and the tissue inhibitors of metalloproteinases (TIMPs) is as critical as the proper production of extracellular matrix. We investigate the role of TIMPs and MMPs in the pathogenesis of keloids and examine the therapeutic potential of TIMP-2. The expression of TIMPs and MMPs in most inflamed parts of cultured keloid fibroblasts (KFs) and peripheral normal skin fibroblasts (PNFs) in the same individuals and the reactivity of KFs to cyclic mechanical stretch were analyzed by quantitative real-time polymerase chain reaction and enzyme-linked immunosorbent assay (n = 7). To evaluate the effect of treating KFs with TIMP-2, collagen synthesis was investigated by quantitative real-time polymerase chain reaction and enzyme-linked immunosorbent assay, and microscopic analysis was used to examine the treatment effects of TIMP-2 on ex vivo cultures of keloid tissue (n = 6). TIMP-2 was downregulated in cultured KFs compared with PNFs in the same individuals, and the reduction in TIMP-2 was exacerbated by cyclic mechanical stretch. Administration of TIMP-2 (200 or 300 ng/mL) significantly suppressed expression of Col1A2 and Col3A1 mRNA and collagen type I protein in KFs. TIMP-2 also significantly reduced the skin dermal and collagen bundle thickness in ex vivo cultures of keloid tissue. These results indicated that downregulation of TIMP-2 in KFs is a crucial event in the pathogenesis of keloids, and the TIMP-2 would be a promising candidate for the treatment of keloids.
- Open Access
- 1 May 2015
- Published by Elsevier in Molecular Therapy
- Vol. 23, S282
707. Prolonged Survival and Improved Phenotypes of Lethal Hypophosphatasia Model Mice By Adeno-Associated Virus-Mediated Muscle Transduction of Bone-Targeted Alkaline Phosphatase
- 1 May 2015
- Published by Elsevier in Molecular Therapy
- Vol. 23, S282
Open Access707. Prolonged Survival and Improved Phenotypes of Lethal Hypophosphatasia Model Mice By Adeno-Associated Virus-Mediated Muscle Transduction of Bone-Targeted Alkaline Phosphatase